Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia-Reference-Cited by-同舟云学术

Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia

Published:2021-04-08 Issue:11 Volume:35 Page:3282-3286
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Tambaro Francesco Paolo,Singh Harjeet^ORCID,Jones Emily,Rytting Michael,Mahadeo Kris M.^ORCID,Thompson Philip^ORCID,Daver Naval,DiNardo Courtney^ORCID,Kadia Tapan^ORCID,Garcia-Manero Guillermo^ORCID,Chan Tim,Shah Rutul R.,Wierda William G.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-021-01232-2.pdf

Reference11 articles.

1. Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, et al. Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience. Am J Hematol. 2018. https://doi.org/10.1002/ajh.25162.

2. Cortes JE, Tallman MS, Schiller GJ, Trone D, Gammon G, Goldberg SL, et al. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood. 2018;132:598–607.

3. DiNardo CD. Ivosidenib in IDH1-mutated acute myeloid leukemia. N. Engl J Med. 2018;379:1186.

4. Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130:722–31.

5. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–44.

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia;Blood;2024-09-12

2. Targeting CD45 by gene-edited CAR T cells for leukemia eradication and hematopoietic stem cell transplantation preconditioning;Molecular Therapy: Oncology;2024-09

3. Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapy;Molecular Therapy: Oncology;2024-09

4. T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting;Molecular Therapy;2024-09

5. OMIP‐106: A 30‐color panel for analysis of check‐point inhibitory networks in the bone marrow of acute myeloid leukemia patients;Cytometry Part A;2024-08-27